Country: Malta
Language: English
Source: Medicines Authority
DICLOFENAC SODIUM
Proge Farm S.r.l. Baluardo La Marmora, 4 - 28100 - Novara, Italy
M01AB05
DICLOFENAC SODIUM 100 mg
MODIFIED-RELEASE TABLET
DICLOFENAC SODIUM 100 mg
POM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
Withdrawn
2006-09-18
FENADOL D ICLOFENAC MODIFIED-RELEASE TABLETS - SUPPOSITORIES COMPOSITION: Each 100 mg modified-release tablet contains: Active ingredient: Diclofenac sodium 100 mg. Excipients: Microgranular cellulose, Lactose, Starch, Polyvinylpyrrholidon, Magnesium stearate, Hydroxypropylcellulose, Diethylphtalate, Cellulose acetophthalate, Titanium dioxide. Each 100 mg suppository contains: Active ingredient: Diclofenac sodium 100 mg. Excipients: Solid semi- synthetic glyceride. PHARMACEUTICAL FORM – PACKAGING 20 modified-release tablets 100 mg - 10 suppositories 100 mg PHARMACO-THERAPEUTICAL CLASS Non-steroidal anti-inflammatory product. MARKETING AUTHORISATION HOLDER PROGE FARM S.r.l. - Baluardo La Marmora, 4 - 28100 NOVARA MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE Modified-release tablets: Omicron Pharma S.r.l., Via Follereau 25, 24027 Nembro (BG) - Italy Suppositories: Fulton Medicinali S.p.A., Via Marconi 28/9, Arese (MI) - Italy THERAPEUTIC INDICATIONS Inflammatory and degenerative rheumatic affections like: rheumatoid arthritis and ankylosing spondylitis; arthrosis; extra-articular rheumatism. Pain caused by extra – rheumatic or post- traumatic inflammation. Symptomatic treatment of primary dysmenorrhea (menstrual pain). CONTRAINDICATIONS Hypersensitivity to components or chemically-related substances. This product should not be used in case of gastric or duodenal ulcer, serious gastroenteric disorders, serious kidney and/or hepatic insufficiency, during pregnancy and nursing, during intense therapy with diuretics, in patients with ongoing haemorrhage and haemorrhagic disposition, in case of haemopoiesis alterations and concomitant treatment with anticoagulants since a synergetic action may occur. Diclofenac, like other non-steroidal anti-inflammatory substances, is contraindicated in patients showing urticaria or acute rhinitis after intake of acetylsalicylic acid or other drugs wh Read the complete document
Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL SPECIALITY FENADOL 100 mg modified-release tablets FENADOL 100 mg suppositories 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _ _ _Modified-release tablets 100 mg_: each tablet contains: active ingredient: Diclofenac sodium 100 mg _Suppositories 100 mg_: each suppository contains: active ingredient: Diclofenac sodium 100 mg For excipients, see 6.1. 3. PHARMACEUTICAL FORM 100 mg modified-release tablets – 20 tablets 100 mg suppositories – 10 suppositories 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Inflammatory and degenerative rheumatic affections: rheumatoid arthritis, ankylosing spondylitis; arthroses; extra-articular rheumatism; painful conditions from phlogosis with extra-rheumatic or post-traumatic origin; symptomatic treatment of primary dysmenorrhea. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION _ _ _Modified- release tablets_: one tablet daily. If the symptoms are more marked during the night or in the morning, FENADOL should be preferably taken in the evening. The tablets must be swallowed whole with water, preferably during the meals. The use of the product is limited to adults. In the treatment of aged patients the posology must be carefully established by the physician, who will have to evaluate a possible reduction of the above mentioned doses. _Suppositories: _suppositories are particularly indicated to eliminate or relieve the nightly pain and the morning rigidity. Posology is one suppository daily, given in the evening before to go to bed. Administer only by rectal way. 4.3. CONTRAINDICATIONS Hypersensitivity towards the components and towards substances strictly related from the chemical point of view. The product should not be used in case of gastric or duodenal ulcer, of severe gastroenteric disorders, of severe renal and/or hepatic insuffici Read the complete document